Does nivolumab work the same in older vs younger patients?
Age can change how patients tolerate treatment, but age alone has not been shown to meaningfully reduce nivolumab efficacy. Clinical data across multiple tumor types show that overall response and disease control with nivolumab are generally maintained in older adults, with the main age-related differences showing up more clearly in safety and treatment discontinuation rather than loss of anti-tumor activity. [1][2]
How do clinical trials analyze efficacy by age?
Trials and pooled analyses typically evaluate efficacy by splitting participants into age groups (for example, <65 vs ≥65, or quartiles by age) and then comparing outcomes such as:
- overall response rate (ORR)
- progression-free survival (PFS)
- overall survival (OS)
Across these analyses, response and survival outcomes with nivolumab tend to be comparable between older and younger groups, suggesting that age does not substantially diminish the drug’s ability to control cancer. [1][2]
What changes with age: efficacy or safety?
The most consistent age effect is on tolerability rather than effectiveness. Older patients more often experience adverse events that can lead to dose delays or discontinuation, and they may be more likely to have comorbidities that complicate immune-related adverse event management. That said, these are safety and management issues rather than evidence of reduced efficacy. [1][2]
Are there any limits to what we can infer from age subgroup results?
Age subgroup comparisons are often limited by sample size once patients are split into bins, and older groups may have different baseline characteristics (like disease burden and performance status). Even with these limitations, the overall pattern in available trial analyses is that nivolumab efficacy remains broadly similar across age groups, with safety driving more of the variability seen in real-world outcomes. [1][2]
Practical implications for clinicians and patients
When deciding on nivolumab for older adults, the key considerations usually revolve around health status and the risk of immune-related side effects, not an expectation that age will blunt the drug’s anti-tumor effect. Older patients still need careful monitoring and prompt management of immune toxicities, but age itself is not a reason to assume nivolumab will be ineffective. [1][2]
---
Sources
- Roche/Genentech. Nivolumab (Opdivo) prescribing information (age subgroup efficacy and general clinical efficacy context). https://www.accessdata.fda.gov/drugsatfda_docs/label/
- EMA. Opdivo EPAR and assessment documents (clinical efficacy across populations, including older patients). https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo